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ABSTRACT
Purpose
Immunotherapy (IT) has been shown to improve cancer survival but there is limited evidence regarding
use in patients with advanced cancer and pre-existing autoimmune disease (AI). We sought to address
these knowledge gaps and determine IT utilization patterns and overall survival (OS) for these patients.
Patients and Methods
This retrospective cohort study used data from Flatiron Health’s nationwide oncology database. Patients
diagnosed with advanced cancer where there was ≥ 1 FDA approved IT were included. Baseline
demographics were analyzed using χ2 and t-tests. Patterns of IT use were assessed using logistic
regression. OS was estimated using Kaplan-Meier and Cox proportional hazards models.
Results
Of the 70,964 patients included, 1,801 had AI. Controlling for demographic and clinical variables, AI was
not associated with IT use in general (Odds Ratio [OR]=0.90, 95% CI 0.79-1.03), but was associated with
lower odds of receiving first-line IT (OR=0.72, 95% CI 0.61-0.84). IT usage differed by cancer type.
Overall, on multivariate analysis, patients with AI had better survival than those without AI. This
remained true for overall IT (Hazard Ratio [HR]=0.86, 95% CI 0.81-0.91) and for first-line IT (HR=0.79,
95% CI 0.71-0.88). Interaction between IT and AI was significant, with IT having stronger association in
patients with AI compared to those without (HR=0.57, 95% CI 0.50-0.64 vs HR=0.66, 95% CI 0.64-0.68).
Among patients treated with IT, interaction between first-line IT and AI was not significant. Among
patients with AI, receiving first-line IT had no survival benefit (HR=0.95, 95% CI 0.77-1.17).
Conclusion
Receipt of IT had greater survival benefit for patients with AI compared to those without AI; first-line IT
did not result in further survival benefit. Patients with advanced cancer and pre-existing AI should
receive IT, potentially as second or third-line treatment.
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INTRODUCTION
Background
Cancer immunotherapy involves treatment that better allows the immune system to detect and target
tumor cells. Immunotherapy has been shown to improve survival in many promising reports regarding
treatment regimens such as immune checkpoint inhibitors and CAR T-cell therapies (1-5), but even
though the use of cancer immunotherapy has been rapidly increasing, there is still limited evidence
regarding use in patients with pre-existing autoimmune disease. The side effects of immunotherapy
include excessive inflammatory responses due to errors in self-recognition by the immune system (6)
which is especially relevant for patients with autoimmune diseases because the immune systems of
these patients are already prone to erroneously targeting healthy self-tissue as foreign tissue. Thus,
even though 10-30% of patients have both cancer and an autoimmune disease (7), immunotherapy is
often not recommended for patients with pre-existing autoimmune disease.
A series of case reports (8-13) has suggested that patients with both cancer and autoimmune disease
may respond just as well as patients without autoimmune disease. These patients may potentially
receive immunotherapy as second or third-line treatment instead of first-line treatment. However,
because this patient demographic has been excluded from previous clinical trials involving cancer
immunotherapy due to concerns of exacerbating pre-existing autoimmune diseases (14), the benefits of
immunotherapy are unclear and it is uncertain whether or not patients with autoimmune disease have
poorer prognosis. The first clinical trial in this patient population was recently initiated (15) in a cohort
of 260 patients with advanced cancer and autoimmune disease that will receive the immune checkpoint
inhibitor nivolumab.
Given these knowledge gaps, we sought to determine the utilization patterns and survival outcomes of
patients with both cancer and autoimmune diseases treated with immunotherapy. Demonstrating that
patients with existing autoimmune disease receive immunotherapy during routine-care and have clinical
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outcomes similar to those without pre-existing autoimmune conditions could increase the use of
immunotherapy in this at-risk population.
Objectives
Our primary objective was to measure immunotherapy use patterns between patients with and without
pre-existing autoimmune disease. We hypothesized that patients with autoimmune disease and
advanced cancer would be less likely to receive immunotherapy compared to advanced cancer patients
with no autoimmune disease.
Our secondary objectives were to assess overall survival (OS) outcomes among patients with and
without pre-existing autoimmune disease who had received immunotherapy. We hypothesized that
survival would be similar between those with and without pre-existing autoimmune conditions, after
controlling for line of treatment when immunotherapy was initiated.

MATERIALS AND METHODS
Study Design
This was a retrospective cohort study that used patient-level data from Flatiron Health’s nationwide
electronic health record (EHR) oncology database.
Data Sources
Flatiron Health’s EHR oncology database provides longitudinal, deidentified health record data
abstracted from structured and unstructured information sources (16). At the time of data collection,
the database included more than 265 cancer clinics across the United States, representing more than 2
million patients (17). Due to the nature of secondary analysis of de-identified data, this study received
designation as non-human subjects research from the Yale University Institutional Review Board.
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Cohort Selection
Patients diagnosed with advanced cancers in which there was at least 1 FDA approved immunotherapy
from January 1, 2011 to June 30, 2019 (date of data cut-off) were included in this analysis. A total of 7
cancer types were included: melanoma, non-small cell lung cancer (NSCLC), gastric cancer, urothelial
carcinoma, head and neck cancer, metastatic colorectal cancer, and metastatic renal cell carcinoma. This
data set excluded patients with a gap >90 days between diagnosis and first visit or medication order.
Only the primary cancer was included for patients with more than 1 diagnosis of advanced cancer.
Patients were excluded if they did not receive any form of systemic therapy (i.e. immunotherapy and
chemotherapy) or if they had missing data for gender (Figure 1).
Outcome Measures
Baseline demographic and clinical characteristics of patients were documented. The most recent Eastern
Cooperative Oncology Group (ECOG) performance status and insurance type following diagnosis of
advanced diseases were identified. International Classification of Diseases, Ninth and Tenth Revision
(ICD-9, ICD-10) codes were used for classification of autoimmune disease (Appendix 1). Details of
medications administered after diagnosis of advanced disease were documented and data on first-line
of treatment after diagnosis of advanced disease were extracted. Median OS was defined as date of
advanced cancer diagnosis to last day in their month of death. Patients who had not died by the end of
the study were censored at the data cut-off date of June 30, 2019.
Statistical Analyses
All statistical analyses were performed using SAS University Edition (SAS Institute Inc, Cary, NC). Baseline
demographics were analyzed using χ2 tests and t-tests for categorical and continuous variables,
respectively. Patterns of immunotherapy use in general and as first-line therapy after diagnosis of
advanced disease were assessed using logistic regression and the Wald χ2 test. Kaplan-Meier methods
were used to estimate the median OS from diagnosis of advanced cancer. Patients with length of follow-
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up shorter than 30 days were excluded from the survival analyses. Cox proportional hazards models
were used to estimate differences in OS between those with and without autoimmune disease. The logrank test was used to assess differences in survival and the Wald χ2 test was used to assess differences
in hazards.

RESULTS
Patient Characteristics
A total of 70,964 patients who were diagnosed with advanced cancer and treated with systemic therapy
(i.e. immunotherapy and/or chemotherapy) between January 1, 2011, and June 30, 2019 were identified
and included in this study. Of these patients, 1,801 had a pre-existing diagnosis of autoimmune disease
and 69,163 did not have such a diagnosis. Compared to those with no autoimmune disease, patients
with autoimmune disease were older (67 vs 66 years, p=0.031) and more likely to be female (50.51% vs
38.8%, p<0.001), be White (78.40% VS 70.93%, p<0.001), be on Medicare (20.38% vs 14.20%, p<0.001),
have received care at an academic center (24.54% vs 6.99%, p<0.001), have Melanoma or NSCLC
(10.61% vs 6.30% and 54.75% vs 47.78%, p<0.001), and have an ECOG value of 2 or ≥3 (11.38% vs
10.30% and 2.83% vs 2.40%, p=0.008) (Table 1).
Patients with autoimmune disease were more likely to have received immunotherapy in general
(41.98% vs 36.58%, p<0.001) and as first-line treatment (25.10% vs 22.11%, p=0.003) (Table 1).
Immunotherapy Usage Patterns
After controlling for age, year of advanced diagnosis, cancer type, gender, race, practice type, insurance
status, ECOG value, and smoking status, autoimmune disease was not associated with use of
immunotherapy in general (Odds Ratio [OR]=0.90, 95% CI 0.79-1.03), but was associated with being less
likely to receive immunotherapy as first-line treatment (OR=0.72, 95% CI 0.61-0.84) (Table 2). The
interaction effect between practice type and autoimmune disease was not significant with regards to
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receipt of immunotherapy in general (p=0.786) and receipt of immunotherapy as first-line treatment
(p=0.238).
We also conducted stratified analyses based on cancer type. Use of immunotherapy in general and as
first-line was most common in metastatic RCC and melanoma for patients with and without
autoimmune disease (Figure 2). In metastatic CRC and gastric cancer, few patients received first-line
immunotherapy, but a substantial proportion of patients with autoimmune disease received
immunotherapy in general compared to those without autoimmune disease (Figure 2).
Overall Survival
Overall, patients with autoimmune disease had better median survival than patients without
autoimmune disease (749 vs 605 days). Of the patients who did not have autoimmune disease, those
who did not receive immunotherapy had a median survival of 512 days and those who did receive
immunotherapy had a median survival of 822 days (Figure 3). Of the patients who did have autoimmune
disease, those who did not receive immunotherapy had a median survival of 531 days and those who
did receive immunotherapy had a median survival of 1152 days (Figure 3). Using the Cox proportional
hazards model to control for age, year of advanced diagnosis, cancer type, gender, race, practice type,
insurance status, ECOG value, and smoking status, having autoimmune disease remained associated
with better survival outcome (Hazard Ratio [HR]=0.86, 95% CI 0.81-0.91) (Table 3). The interaction
between immunotherapy and autoimmune disease was significant (p=0.018) (Table 3).
Among patients treated with immunotherapy, those who did not have autoimmune disease and did not
receive first-line immunotherapy had a median survival of 764 days and those who did receive first-line
immunotherapy had a median survival of 941 days (Figure 4). Among patients treated with
immunotherapy, those who did have autoimmune disease and did not receive first-line immunotherapy
had a median survival of 993 days and those who did receive first-line immunotherapy had a median
survival of 1603 days (Figure 4). Using the Cox proportional hazards model to control for age, year of
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advanced diagnosis, cancer type, gender, race, practice type, insurance status, ECOG value, and smoking
status, having autoimmune disease remained associated with better survival outcome (HR=0.79, 95% CI
0.71-0.88) (Table 4). The interaction between first-line immunotherapy and autoimmune disease was
not significant (p=0.469) (Table 4).

DISCUSSION
Conclusions
Upon univariate analysis, patients with autoimmune disease were more likely to receive immunotherapy
in general and as first-line treatment compared to patients without autoimmune disease. However,
after controlling for demographic and clinical variables, we observed that autoimmune disease was not
associated with immunotherapy use in general and was associated with a lower likelihood of receiving
immunotherapy as first-line treatment.
We also observed differences in immunotherapy usage by cancer types. The high proportion of patients
receiving both immunotherapy in general and as first-line treatment in melanoma and metastatic RCC is
likely because these types of cancer have had a more established history of immunotherapy and such
treatments are part of the current standard of care (18,19). On the other hand, immunotherapy is still a
relatively new treatment modality in cancers such as metastatic CRC and gastric cancer (20,21), which is
likely why fewer patients in these groups were observed to receive immunotherapy as a first-line
treatment.
Overall, patients with autoimmune disease had better survival than those without autoimmune disease.
This remained true in patients who received overall immunotherapy and in patients who received firstline immunotherapy. This was unexpected and the interpretation of these findings should be careful.
There are mixed conclusions within the limited literature on survival in patients with advanced cancer
and autoimmune disease. In a study on autoimmune diseases and mortality risk in sepsis (22), the
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authors found that those with autoimmune disease had lower 30-day mortality risk unrelated to
mechanisms associated with chronic use of immunomodulation medications. Specifically, these were
autoimmune diseases associated with the overexpression of pro-inflammatory cytokines IL-12 and INF-γ.
The authors posit that the immunosuppressive state induced by sepsis may have a critical role in
mortality (22) and thus survival may have been improved by the increased expression of IL-12 and INF-γ
brought about by autoimmune disease. This is relevant in cancer populations since tumors are also
actively immunosuppressive, both inside and outside the tumor microenvironment (23). Additionally, a
study on survival in patients with autoimmune disease and lung cancer (24) showed that having
autoimmune disease did not influence prognosis. The authors argue that this may be due to the
inherently poor prognosis of lung cancer (24) since in a previous study, they found that despite
increased risk of death in patients with autoimmune disease in cancers with intermediary prognosis,
mortality in patients with autoimmune disease did not increase for stomach cancer which has poor
prognosis (25).
The interaction between immunotherapy and autoimmune disease was significant, with receipt of
immunotherapy having a larger magnitude of effect in patients with autoimmune disease compared to
those without autoimmune disease (HR=0.57, 95% CI 0.50-0.64 vs HR=0.66, 95% CI 0.64-0.68). Among
patients treated with immunotherapy, the interaction between first-line immunotherapy and
autoimmune disease was not significant. The survival curves crossed for patients with autoimmune
disease who received versus did not receive first-line immunotherapy. Among patients with
autoimmune disease, receiving first-line immunotherapy did not result in significant survival benefit
(HR=0.95, 95% CI 0.77-1.17).
Limitations
This was a retrospective study and thus relied on pre-existing data. However, we are confident in the
quality and comprehensiveness of the data provided by Flatiron Health. In our analyses, we included all
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patients who had ever been diagnosed with an autoimmune disease and did not specify when
autoimmune disease was diagnosed i.e. whether it was before or after the initiation of systemic therapy.
This could introduce bias because autoimmune disease is generally a contraindication for
immunotherapy, so oncologists may be more likely to indicate a diagnosis of autoimmune disease when
they are considering immunotherapy. It is also unclear whether our data includes patients who were
treated in other facilities for early stage disease and then subsequently received treatment for advanced
disease at Flatiron Health-affiliated clinics. Overall, some of the cancer types included in this study had
low absolute numbers of patients who had autoimmune disease and received immunotherapy.
Recommendations
Our findings show that receipt of immunotherapy had greater survival benefit for patients with
autoimmune disease compared to those without autoimmune disease and that receipt of first-line
immunotherapy did not result in further survival benefit among patients with autoimmune disease. This
is clinically meaningful as it suggests that patients with advanced cancer and autoimmune disease
should receive immunotherapy and that whether or not this is given as a first-line treatment is
unimportant to survival. Taking into consideration the potential side effects of immunotherapy in this
patient population, clinical practices should give thought to adopting immunotherapy regimens later on
in the treatment pathway. The intersection between autoimmune disease and cancer is understudied
and more research in this area is needed to better understand the nuances observed in this study. We
await the results of the recently initiated phase Ib nivolumab trial in this patient population to confirm
our present findings.

FIGURES AND TABLES
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Table 1: Baseline Patient Characteristics
Autoimmune Disease
(n = 1,801)
Age (Mean)
67
Advanced Cancer Diagnosis Year
2011
2012
2013
2014
2015
2016
2017
2018
2019

95 (5.27%)
120 (6.68%)
198 (11.05%)
255 (14.14%)
293 (16.22%)
267 (14.81%)
289 (16.11%)
234 (13.02%)
50 (2.69%)

No Autoimmune Disease
(n = 69,163)
66

p-value

3,674 (5.31%)
4,895 (7.08%)
7,794 (11.27%)
8,968 (12.97%)
10,116 (14.63%)
10,564 (15.27%)
10,674 (15.43%)
9,629 (13.92%)
2,849 (4.12%)

0.0552

0.0311

<0.0012

Gender
Female 915 (50.81%)
Male 886 (49.19%)

26,853 (38.8%)
42,310 (61.17%)
<0.0012

Race
White
Black
Asian
Other
Unknown
Insurance Type
Commercial Health Plan
Medicaid
Medicare
Other
Unknown
Practice Type
Academic
Community
Smoking status
History of smoking
No history of smoking
Unknown
Cancer Type
Bladder Cancer
Colorectal Cancer
Gastric Cancer
Head and Neck Cancer
Melanoma
Non-Small Cell Lung Cancer
Renal Cell Carcinoma

1,412 (78.40%)
118 (6.55%)
26 (1.44%)
127 (7.05%)
118 (6.55%)

49,059 (70.93%)
5,419 (7.84%)
1,444 (2.09%)
7,183 (10.39%)
6,058 (8.76%)
<0.0012

749 (41.59%)
66 (3.66%)
367 (20.38%)
127 (7.05%)
492 (27.32%)

30,092 (43.51%)
3,025 (4.37%)
9,824 (14.20%)
6,911 (9.99%)
19,311 (27.92%)
<0.0012

442 (24.54%)
1,359 (75.46%)

4,836 (6.99%)
64,327 (93.01%)
0.1812

1,087 (60.36%)
233 (12.94%)
481 (26.71%)

41,393 (59.85%)
8,194 (11.85%)
19,576 (28.30%)
<0.0012

104 (5.77%)
280 (15.55%)
101 (5.61%)
73 (4.05%)
191 (10.61%)
986 (54.75%)
66 (3.66%)

4,957 (7.17%)
14,653 (21.19%)
5,716 (8.26%)
4,148 (6.00%)
4,359 (6.30%)
33,048 (47.78%)
2,282 (3.30%)

ECOG Value
0 468 (25.99%)

20,483 (29.62%)

0.0082
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Immunotherapy

1
2
≥3
Unknown

582 (32.32%)
205 (11.38%)
51 (2.83%)
495 (27.48%)

Yes 756 (41.98%)
No 1,045 (58.02%)

22,242 (32.16%)
7,124 (10.30%)
1,658 (2.40%)
17,656 (25.53%)
25,300 (36.58%)
43,863 (63.42%)

0.0032

Immunotherapy as First-line
Yes 452 (25.10%)
No 1,349 (74.90%)
1

<0.0012

15,294 (22.11%)
53,869 (77.89%)

T-test, 2Chi-squared test

Figure 1: Patient Flow Diagram
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Table 2: Logistic regression of covariates associated with immunotherapy use
Overall Immunotherapy
First-line Immunotherapy
OR
95% CI
p-value
OR
95% CI
p-value
Age (Continuous)
1.00
1.00-1.00
<0.001
1.01
1.01-1.01
<0.001
Autoimmune Disease
No 1.00
1.00-1.00
Reference 1.00
1.00-1.00
Reference
Yes 0.90
0.79-1.03
0.112
0.72
0.61-0.84
<0.001
Advanced Cancer Diagnosis
Year
2011 1.00
1.00-1.00
Reference 1.00
1.00-1.00
Reference
2012 1.45
1.22-1.72
<0.001
1.26
0.99-1.61
0.062
2013 2.67
2.28-3.13
<0.001
1.86
1.48-2.33
<0.001
2014 5.12
4.39-5.96
<0.001
2.89
2.32-3.59
<0.001
2015 12.41
10.69-14.40
<0.001
5.44
4.41-6.70
<0.001
2016 18.52
15.95-21.49
<0.001
10.74
8.75-13.19
<0.001
2017 30.80
26.52-35.77
<0.001
28.91
23.60-35.42
<0.001
2018 41.34
35.53-48.10
<0.001
49.98
40.77-61.27
<0.001
2019 27.78
23.44-32.93
<0.001
65.63
52.74-81.68
<0.001
Gender
Male 1.00
1.00-1.00
Reference 1.00
1.00-1.00
Reference
Female 1.08
1.04-1.13
<0.001
1.09
1.03-1.14
0.003
Race
White 1.00
1.00-1.00
Reference 1.00
1.00-1.00
Reference
Black 0.91
0.84-0.98
0.014
0.86
0.78-0.95
0.003
Asian 1.06
0.91-1.22
0.460
1.04
0.86-1.25
0.715
Other 1.01
0.95-1.09
0.711
0.95
0.87-1.03
0.197
Unknown 0.73
0.67-0.78
<0.001
0.85
0.78-0.93
<0.001
Insurance Type
Commercial Health Plan 1.00
1.00-1.00
Reference 1.00
1.00-1.00
Reference
Medicaid 0.78
0.70-0.87
<0.001
0.80
0.70-0.92
0.001
Medicare 1.05
0.98-1.11
0.173
1.02
0.94-1.10
0.643
Other 1.22
1.13-1.31
<0.001
1.07
0.99-1.17
0.108
Unknown 0.90
0.86-0.95
<0.001
1.01
0.95-1.08
0.718
Practice Type
Community 1.00
1.00-1.00
Reference 1.00
1.00-1.00
Reference
Academic 1.51
1.40-1.64
<0.001
1.66
1.51-1.82
<0.001
Smoking status
No history of smoking 1.00
1.00-1.00
Reference 1.00
1.00-1.00
Reference
History of smoking 0.84
0.78-0.89
<0.001
0.84
0.77-0.90
<0.001
Unknown 0.42
0.30-0.57
<0.001
0.69
0.44-1.06
0.092
Cancer Type
Bladder Cancer 0.78
0.73-0.84
<0.001
0.82
0.75-0.89
<0.001
Colorectal Cancer 0.06
0.04-0.08
<0.001
0.04
0.02-0.06
<0.001
Gastric Cancer 0.07
0.07-0.08
<0.001
0.04
0.03-0.04
<0.001
Head and Neck Cancer 0.73
0.68-0.79
<0.001
0.68
0.62-0.75
<0.001
Melanoma 150.03 104.56-215.27 <0.001
270.75 170.98-428.75 <0.001
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Non-Small Cell Lung Cancer
Renal Cell Carcinoma
ECOG Value
0
1
2
≥3
Unknown

1.00
36.43

1.00-1.00
29.62-44.81

Reference
<0.001

1.00
119.50

1.00-1.00
99.31-143.81

Reference
<0.001

1.00
0.91
0.74
0.59
0.52

1.00-1.00
0.87-0.96
0.69-0.80
0.51-0.67
0.49-0.55

Reference
<0.001
<0.001
<0.001
<0.001

1.00
1.04
1.09
1.26
0.81

1.00-1.00
0.97-1.10
1.00-1.19
1.08-1.47
0.75-0.87

Reference
0.282
0.043
0.003
<0.001

Figure 2: Immunotherapy Usage by Cancer Type

a) Percentage of patients receiving immunotherapy in general

b) Percentage of patients receiving immunotherapy first-line
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Figure 3: Overall Survival in Patients Receiving Immunotherapy

*0 is no AI and no IT, 1 is no AI yes IT, 10 is yes AI no IT, 11 is yes AI yes IT

T a ble 3: Cox-regression of covariates associated with overall mortality in all patients
Mo d el 1

HR

Au toimmune Disease

I m munotherapy

No 1.00
Yes 0.86
No
Yes

-

Mo d el 2

Mo d el 3

95% CI

p- value

HR

95% CI

p- value

1.00-1.00
0.81-0.91

Reference
<0.001

1.00
0.86

1.00-1.00
0.81-0.91

Reference
<0.001

-

-

Reference
0.007

-

-

1.00

1.00-1.00

Reference
<0.001

-

-

Reference
<0.001
0.018

0.66

0.64-0.68

HR

95% CI

p- value

I n teraction Term
I T Yes vs No*AI No
0.66 0.64-0.68
I T Yes vs No*AI Yes
0.57 0.50-0.64
All 3 models include the following covariates: age (continuous), year of advanced diagnosis, cancer type, gender, race, practice type,
insurance status, ECOG value, smoking status.
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Figure 4: Overall Survival in Patients Receiving Immunotherapy First-line

*Among patients treated with IT: 0 is no AI and no IT first-line, 1 is no AI yes IT first-line, 10 is yes AI
no IT first-line, 11 is yes AI yes IT first-line

T a ble 4: Cox-regression of covariates associated with overall mortality in patients treated with
i m munotherapy
Mo d el 1

Au toimmune Disease

HR

95% CI

Mo d el 2

p- value

HR

95% CI

p- value

No 1.00 1.00-1.00
Reference 1.00 1.00-1.00 Reference
Yes 0.79 0.71-0.88
<0.001
0.79 0.71-0.88 <0.001
I m munotherapy as First-line
No
1.00 1.00-1.00 Reference
Yes
1.02 0.98-1.06 0.282
Both models include the following covariates: age (continuous), year of advanced diagnosis, cancer type, gender,
race, practice type, insurance status, ECOG value, smoking status.
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APPENDICES
Appendix 1: ICD-9 and ICD-10 Codes for Autoimmune Disease
ICD Code Code System
Disease
M06.1
ICD-10-CM
Adult-onset Still's disease
720
ICD-9-CM
Ankylosing spondylitis
M45.9
ICD-10-CM
Ankylosing spondylitis of unspecified sites in spine
283
ICD-9-CM
Autoimmune hemolytic anemias
E06.3
ICD-10-CM
Autoimmune thyroiditis
136.1
ICD-9-CM
Behcet's syndrome
K90.0
ICD-10-CM
Celiac disease
579
ICD-9-CM
Celiac disease
582.1
ICD-9-CM
Chronic glomerulonephritis with lesion of membranous
582
ICD-9-CM
Chronic glomerulonephritis with lesion of proliferative
glomerulonephritis
582.9
ICD-9-CM
Chronic glomerulonephritis with unspecified pathological lesion in
kidney
245.2
ICD-9-CM
Chronic lymphocytic thyroiditis
N03.2
ICD-10-CM
Chronic nephritic syndrome with diffuse membranous
glomerulonephritis
N03.9
ICD-10-CM
Chronic nephritic syndrome with unspecified morphologic changes
M34.1
ICD-10-CM
CR(E)ST syndrome
K50.10
ICD-10-CM
Crohn's disease of large intestine without complications
K50.00
ICD-10-CM
Crohn's disease of small intestine without complications
K50.90
ICD-10-CM
Crohn's disease, unspecified, without complications
710.3
ICD-9-CM
Dermatomyositis
M33.90
ICD-10-CM
Dermatopolymyositis, unspecified, organ involvement unspecified
D59.0
ICD-10-CM
Drug-induced autoimmune hemolytic anemia
714.1
ICD-9-CM
Felty's syndrome
L40.1
ICD-10-CM
Generalized pustular psoriasis
446.5
ICD-9-CM
Giant cell arteritis
N08
ICD-10-CM
Glomerular disorders in diseases classified elsewhere
M31.0
ICD-10-CM
Hypersensitivity angiitis
K51.40
ICD-10-CM
Inflammatory polyps of colon without complications
K51.50
ICD-10-CM
Left sided colitis without complications
556.5
ICD-9-CM
Left-sided ulcerative (chronic) colitis
G35
ICD-10-CM
Multiple sclerosis
340
ICD-9-CM
Multiple sclerosis
G70.01
ICD-10-CM
Myasthenia gravis with (acute) exacerbation
G70.00
ICD-10-CM
Myasthenia gravis without (acute) exacerbation
21

358
696.5
D59.1
M31.6
L40.8
696.1
696.8
L40.59
714.2
L44.8
556.8
K51.80
696.2
M08.40
281
L41.0
696.3
L44.0
725
710.4
M34.0
556.4
696
555.1
555
555.9
714
M05.60

ICD-9-CM
ICD-9-CM
ICD-10-CM
ICD-10-CM
ICD-10-CM
ICD-9-CM
ICD-9-CM
ICD-10-CM
ICD-9-CM
ICD-10-CM
ICD-9-CM
ICD-10-CM
ICD-9-CM
ICD-10-CM
ICD-9-CM
ICD-10-CM
ICD-9-CM
ICD-10-CM
ICD-9-CM
ICD-9-CM
ICD-10-CM
ICD-9-CM
ICD-9-CM
ICD-9-CM
ICD-9-CM
ICD-9-CM
ICD-9-CM
ICD-10-CM

M06.9
M05.10
135
D86.9
V82.1
710.2
M35.01
M35.00
710

ICD-10-CM
ICD-10-CM
ICD-9-CM
ICD-10-CM
ICD-9-CM
ICD-9-CM
ICD-10-CM
ICD-10-CM
ICD-9-CM

Myasthenia gravis without (acute) exacerbation
Other and unspecified pityriasis
Other autoimmune hemolytic anemias
Other giant cell arteritis
Other psoriasis
Other psoriasis
Other psoriasis and similar disorders
Other psoriatic arthropathy
Other rheumatoid arthritis with visceral or systemic involvement
Other specified papulosquamous disorders
Other ulcerative colitis
Other ulcerative colitis without complications
Parapsoriasis
Pauciarticular juvenile rheumatoid arthritis, unspecified site
Pernicious anemia
Pityriasis lichenoides et varioliformis acuta
Pityriasis rosea
Pityriasis rubra pilaris
Polymyalgia rheumatica
Polymyositis
Progressive systemic sclerosis
Pseudopolyposis of colon
Psoriatic arthropathy
Regional enteritis of large intestine
Regional enteritis of small intestine
Regional enteritis of unspecified site
Rheumatoid arthritis
Rheumatoid arthritis of unspecified site with involvement of other
organs and systems
Rheumatoid arthritis, unspecified
Rheumatoid lung disease with rheumatoid arthritis of unspecified site
Sarcoidosis
Sarcoidosis, unspecified
Screening for rheumatoid arthritis
Sicca syndrome
Sicca syndrome with keratoconjunctivitis
Sicca syndrome, unspecified
Systemic lupus erythematosus
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M32.10

ICD-10-CM

710.1
M34.9
E05.00
242
556
556.1
K51.00
556.2
K51.20
K51.30
556.9
K51.90
556.6
D51.0
L80
709.01

ICD-9-CM
ICD-10-CM
ICD-10-CM
ICD-9-CM
ICD-9-CM
ICD-9-CM
ICD-10-CM
ICD-9-CM
ICD-10-CM
ICD-10-CM
ICD-9-CM
ICD-10-CM
ICD-9-CM
ICD-10-CM
ICD-10-CM
ICD-9-CM

Systemic lupus erythematosus, organ or system involvement
unspecified
Systemic sclerosis
Systemic sclerosis, unspecified
Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm
Toxic diffuse goiter without mention of thyrotoxic crisis or storm
Ulcerative (chronic) enterocolitis
Ulcerative (chronic) ileocolitis
Ulcerative (chronic) pancolitis without complications
Ulcerative (chronic) proctitis
Ulcerative (chronic) proctitis without complications
Ulcerative (chronic) rectosigmoiditis without complications
Ulcerative colitis, unspecified
Ulcerative colitis, unspecified, without complication
Universal ulcerative (chronic) colitis
Vitamin B12 deficiency anemia due to intrinsic factor
Vitiligo
Vitiligo
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*Cells with less than 1% of patients were consolidated into the “Other” category which includes:
Dermatopolymyositis, Giant cell arteritis, Ankylosing spondylitis, Inflammatory polyps of colon,
Pseudopolyposis of colon, Polymyositis, Chronic nephritic syndrome, Hypersensitivity angiitis, Adultonset Still's disease, Other and unspecified pityriasis, Pityriasis lichenoides et varioliformis acuta,
Pityriasis rubra pilaris

Appendix 3: Types of Immunotherapy First Received by Patients

*Cells with less than 1% of patients were consolidated into the “Other” category which includes:
aldesleukin, peginterferon alfa-2b, talimogene laherparepvec, bcg vaccine, avelumab, sipuleucel-t,
cemiplimab, interferon alfa-2a
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